Day: January 25, 2024

LOUISVILLE, Ky., Jan. 25, 2024 (GLOBE NEWSWIRE) — Stock Yards Bancorp, Inc. (NASDAQ: SYBT), parent company of Stock Yards Bank & Trust Company, with offices in Louisville, central, eastern and northern Kentucky, as well as the Indianapolis, Indiana and Cincinnati, Ohio metropolitan markets, today announced that Ja Hillebrand, Chairman and CEO, and T. Clay Stinnett, EVP and CFO, will participate in the Janney Annual CEO Forum to be held January 31st to February 1st, and will participate in a series of meetings with institutional investors. Management’s discussion materials to be used at this conference will be posted to the investor section of the Company’s website, www.syb.com, on or before January 31, 2024. Louisville, Kentucky-based Stock Yards Bancorp, Inc., with $8.17 billion in assets, was incorporated in 1988 as a bank...

Toronto, ON, Jan. 25, 2024 (GLOBE NEWSWIRE) — Plato Gold Corp. (TSX-V: PGC) (OTCQB: NIOVF) (Frankfurt: 4Y7 or WKN: A0M2QX) (“Plato” or the “Company”) is pleased to announce the results of its 2023 winter drill program totalling 419 m and 2 drill holes on the Marriott Gold Property, Matheson, Northeastern Ontario. The Marriott Property is located within the Abitibi Greenstone Belt gold mining camp. Plato’s 2023 drill holes are located 11 km east of Agnico Eagle’s Holt gold mining complex. The Marriott drill core displays typical characteristics of Abitibi gold deposits with elevated sulphides and base metals contents:Disseminated sulphides up to 35% in blue basaltic breccia (Figure 1) Disseminated sulphides up to 2% in massive basalt and brecciated basalt Up to 7% pyrite and coarse-grained pyrite up to 2 x 3 cm in size in brecciated...

Community bank brings together lines of business from mortgage to consumer to harness benefits of a single platform WILMINGTON, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) — nCino, Inc. (NASDAQ: NCNO), a pioneer in cloud banking for the global financial services industry, today announced that The Bank of Bennington (Bennington) has adopted nCino’s Consumer Banking Solution, expanding its established relationship with nCino and driving an omnichannel experience across the Bank’s personal banking and mortgage lending business. After seeing efficiency gains in its mortgage operations as a result of its use of nCino’s Mortgage Suite, Bennington saw the value in utilizing a single platform across business lines and made the strategic decision to implement the nCino Consumer Banking Solution. By combining nCino’s cloud-based solutions with...

NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) — Taboola (Nasdaq: TBLA), a global leader in powering recommendations for the open web, today announced that it will release fourth quarter 2023 financial results on Wednesday, February 28, 2024 before market open, followed by a conference call and webcast at 8:30 a.m. ET that same day. Conference call details below: What: Taboola Fourth Quarter 2023 Financial Results Conference Call When: Wednesday, February 28, 2023 at 8:30 a.m. ET Details: Taboola’s senior management team will discuss the Company’s earnings on a call that can be accessed via webcast at https://investors.taboola.com. To access the call by phone, please go to this link to register at https://register.vevent.com/register/BI393f7d9c14614552954ce19d1ff0c2df and you will be provided with dial in details. The webcast...

MONTREAL, Jan. 25, 2024 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive license agreement with Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”), granting Knight the exclusive rights to seek regulatory approval and commercialize IPX203 in Canada and Latin America. IPX203 is a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules designed for the treatment of Parkinson’s disease. Financial terms of the agreement were not disclosed. IPX203 contains immediate-release (IR) granules and extended-release (ER) coated beads. The IR granules consist of CD and LD, with a disintegrant polymer to allow for rapid dissolution. The ER beads consist of LD, coated...

TROY, Mich., Jan. 25, 2024 (GLOBE NEWSWIRE) — Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced that the shareholders of the Company approved an amendment to the Company’s Articles of Incorporation to increase the number of authorized shares of the Company’s common stock from 10,000,000 to 35,000,000 (the “Charter Amendment”), that all its outstanding debt held by CP Acquisitions LLC (the “New Lender”), an entity affiliated with Raymond Chang, the Chief Executive Officer of the Company and a member of the Board of Directors (the “Board”), and I-Tseng Jenny Chan, a member of the Board, has been consolidated under a single convertible note and approximately $3.9 million of the outstanding debt has been converted...

New Data Show Treatment with Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy Resulted in Favorable Structural Remodeling, Improvements in Cardiac Function and Stabilization of Fibrosis SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data at CMR 2024 demonstrating favorable effects on cardiac structure, function and fibrosis related to treatment with aficamten in FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM), the open label extension clinical trial of aficamten in patients with hypertrophic cardiomyopathy (HCM). In many patients with HCM, the left ventricular hypertrophy that characterizes the disease results in elevated cardiac mass, and left ventricular outflow tract (LVOT) obstruction...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CUPERTINO, CA, Jan. 25, 2024 (GLOBE NEWSWIRE) —  Boardwalktech Software Corp. (the “Company” or “Boardwalktech“) (TSXV:BWLK) (OTCQB:BWLKF) announces that it has received an extension from the TSX Venture Exchange (the “TSXV“) with respect to the duration of its previously announced private placement (the “Offering“) pursuant to the Listed Issuer Financing Exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions. The outside date for the final closing and filing of all final documentation in respect of the Offering has been extended from January 25, 2024 to February 24, 2024. For more information about the upsized Offering please refer to the Company’s press...

WALTHAM, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, is pleased to announce changes to its Board of Directors reflecting a strategic move to further align with the company’s growth plans. After nearly a decade of service, Gus Halas is retiring from his position as Chairperson of the Board. During his tenure, he played a pivotal role in shaping OptimizeRx’s success, and we extend our deepest gratitude for his commitment and leadership. Effective immediately, Lynn O’Connor Vos will assume the role of Chairperson of the Board, succeeding Mr. Halas. Ms. Vos has been a seasoned and respected member of the OptimizeRx Board since 2015. She brings...

InflaRx to cover costs of GOHIBIC for patients who are treated in line with its Emergency Use Authorization (EUA) but do not survive. InflaRx is determined to support broader access to GOHIBIC for eligible patients.ANN ARBOR, Mich., Jan. 25, 2024 (GLOBE NEWSWIRE) — InflaRx Pharmaceuticals Inc., a subsidiary of InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that the Company has launched The InflaRx Commitment Program (Commitment Program). Pursuant to the Commitment Program, the cost of GOHIBIC (vilobelimab) will be refunded for up to six (6) administered inpatient doses (the full treatment course) to institutions that meet the eligibility requirements*, for patients who were administered GOHIBIC in line with its EUA and who...